Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

Bibliographic Details
Main Authors:	J.L. Boormans, R. De Wit, G.S. Kulkarni, E.M. Uchio, M. Roumiguié, L.E.M. Krieger, E.A. Singer, D.F. Bajorin, A.M. Kamat, P. Grivas, H.K. Seo, H. Nishiyama, B.R. Konethy, T. Saretsky, H. Li, K. Nam, E. Kapadia, A.V. Balar
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320333723

Similar Items

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results
by: J.M. Piulats, et al.
Published: (2020-07-01)

Pembrolizumab (pembro) for docetaxel-pretreated metastatic Castration-Resistant Prostate Cancer (mCRPC): Update on KEYNOTE-199, cohorts 1-3
by: J.M. Piulats, et al.
Published: (2020-07-01)

KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: S. Feyerabend, et al.
Published: (2020-07-01)

KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC)
by: R. McDermott, et al.
Published: (2020-07-01)

KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)
by: G. Gravis, et al.
Published: (2020-07-01)

P.057 AORTIC DISTENSIBILITY BY NUCLEAR MAGNETIC RESONANCE IN ESENTIAL HYPERTENSION
by: C. Giannattasio, et al.
Published: (2007-08-01)

Impact of molecular subtyping and immune infiltration on response and outcome following neoadjuvant pembrolizumab (pembro), versus neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer
by: A. Necchi, et al.
Published: (2020-07-01)

Keynotes
Published: (2016-01-01)

Golimumab in unresponsive ulcerative colitis
by: Lippert E, et al.
Published: (2014-05-01)

Baryon content of massive galaxy clusters at 0.57
by: Chiu, I, et al.
Published: (2021)

Keynote Speech
by: Windchy, Eli
Published: (2018)

Keynote Abstract
by: Mohd Dato’ Sabarudin, et al.
Published: (2016-01-01)

Keynote Lectures
Published: (2004-01-01)

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
by: Т. V. Korotaeva, et al.
Published: (2018-12-01)

Toponymic Cultural Keynotes in Spanish Gastronomic Thesaurus
by: E V Smirnova
Published: (2015-12-01)

P.057 EFFECTS OF CORONARY MICROCIRCULATION ON INTRACORONARY PRESSURE WAVEFORMS AS ASSESSED BY FAST FOURIER FRANSFORM ANALYSIS
by: E. Stamatopoulos*, et al.
Published: (2007-06-01)

Keynote: The Joy of Research
by: Sommerall, D'Ann
Published: (2021)

KEYNOTE: THE BIOGRAPHY OF OBJECTS
by: C. Greco
Published: (2019-05-01)

Keynote Speaker Abstracts
by: Isnansetyo Alim
Published: (2020-01-01)

OSG-057 Superconducting Gravimeter Noise Levels in Lhasa (China)
by: Miaomiao Zhang, et al.
Published: (2016-01-01)

Evaluation of ADXBLADDER and cytology performance in the follow up of NMIBC: A blinded prospective multicentric study
by: P. Gontero, et al.
Published: (2020-07-01)

Reconstructive trends and complications following parotidectomy: incidence and predictors in 11,057 cases
by: Cory Donovan Bovenzi, et al.
Published: (2019-11-01)

057 EARLY INITIATION OF RENAL REPLACEMENT THERAPY IMPROVES OUTCOME AMONG BURNED PATIENTS WITH ACUTE KIDNEY INJURY
by: Z.H. Liew, et al.
Published: (2017-08-01)

Comparison of performance of ADXBLADDER with urine cytology in NMIBC follow up: a blinded prospective multicentric study
by: P. Gontero, et al.
Published: (2020-10-01)

Xpert® bladder cancer monitor in the follow up of patients affected by non muscle invasive bladder cancer (NMIBC): An update
by: C. D’Elia, et al.
Published: (2020-07-01)

<br><b>Keynotes</b>
by: Jan Erik Frantsvåg
Published: (2015-03-01)

Keynote. Motivation: Theory into Practice
by: David Vawter
Published: (2019-02-01)

On the Future: A Keynote Address
by: Martin John Rees
Published: (2020-02-01)

<br><b>Keynotes</b>
by: Jan Erik Frantsvåg
Published: (2015-03-01)

Recurrence and progression free survival of intermediate risk NMIBC: The impact of conditional evaluation and sub-classification
by: Y. Kohada, et al.
Published: (2020-07-01)

Across the consciousness continuum – from unresponsive wakefulness to sleep
by: Christine eBlume, et al.
Published: (2015-03-01)

Nurses Innovate, Create, and Investigate: Enhancing Patient Care, Keynote
by: Short, Candice, et al.
Published: (2021)

Distinct Pores for Peroxisomal Import of PTS1 and PTS2 Proteins
by: Malayko Montilla-Martinez, et al.
Published: (2015-12-01)

Regulatory T cell activity and signs of T cell unresponsiveness in bovine paratuberculosis
by: Jonathan A Roussey, et al.
Published: (2014-10-01)

What Makes for a Fantastic Conference Keynote Address?
by: Alexander M. Clark, et al.
Published: (2018-10-01)

Intravesical BCG: Possible Protective Impact Against COVID-19 in NMIBC Patients
by: Gabriel GLUCK, et al.
Published: (2020-06-01)

Experiencing the Process of Change,” Keynote Address
by: Bitter, James
Published: (2001)

Process and Movement in Therapy, Keynote Address,
by: Bitter, James
Published: (2001)

Keynote Address for Western Journal Day
by: Jerry White, et al.
Published: (2017-01-01)

DIGAREC Keynote-Lectures 2009/10
by: Aarseth, Espen, et al.
Published: (2011)